Status
Conditions
Treatments
About
The HANSE study is primarily intended as a pilot to provide evidence that a holistic and effective lung cancer screening program can be implemented in Germany and that such a screening program can be integrated in the current infrastructure of certified lung cancer centers.
Full description
Germany has a long history of offering screening programs for cancers, such as breast, colorectal, and, more recently, cervical and skin cancer. Screening for lung cancer, however, which causes more deaths than any other cancer in men and is the second leading cancer death in women (not far behind breast cancer), has not been implemented to date. Only very recently, Institute for Quality and Efficiency in Healthcare (IQWiG) in a preliminary assessment of low-dose CT screening, concluded that the benefits from screening outweigh potential risks. However, an implementation of a national lung cancer screening program, which would be covered by the general health insurance, will likely not be implemented before 2022.
Nonetheless, the IQWiG report also comments on important criteria for implementing lung cancer screening in Germany using low-dose CT:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Comorbidity, which would unequivocally contraindicate either screening or treatment if lung cancer is detected.
History of chest CT within the past year preceding the invitation.
Inability to undergo non-contrast CT (e.g. ≥ 200 kg body weight, inability to lie flat).
Pregnancy
Risk of non-compliance with study procedures.
Primary purpose
Allocation
Interventional model
Masking
12,100 participants in 5 patient groups
Loading...
Central trial contact
Jens Vogel-Claussen, Prof. Dr.; Heiko Hartleb
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal